1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > PharmaPoint: Crohn’s Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - China Drug Forecast and Market Analysis to 2022

Summary

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on GlobalData’s primary research, the majority of Chinese gastroenterologists follow the ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons..

Scope

- Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the China Crohn’s disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in China.

Table Of Contents

PharmaPoint: Crohn’s Disease - China Drug Forecast and Market Analysis to 2022
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables
8
1.2 List of Figures
9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.2 Symptoms 17
3.3 Prognosis 18
3.4 Quality of Life 19
4 Disease Management 20
4.1 Treatment Overview 21
4.2 China 26
4.2.1 Diagnosis 26
4.2.2 Clinical Practice 26
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles - Major Brands 30
5.3.1 Remicade (infliximab) 30
5.3.2 Humira (adalimumab) 36
5.3.3 Cimzia (certolizumab pegol) 40
5.3.4 Tysabri (natalizumab) 44
5.3.5 Other Marketed Products 49
5.4 Biosimilars 50
5.4.1 Introduction 50
5.4.2 Hospira's Inflectra Versus JandJ's Remicade in Key Autoimmune Diseases 51
5.4.3 Biosimilars in the Immunology Community 52
5.4.4 By the Numbers: Biosimilars in Development 52
5.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 54
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 57
6.3 More Therapies for Anti-TNF-Refractory Patients 58
6.4 Unmet Needs Gap Analysis 59
6.5 Targeted Therapies 60
6.6 Predictive Tools for Early Diagnosis and Treatment 61
7 Pipeline Assessment 62
7.1 Overview 62
7.2 Promising Drugs in Clinical Development 62
7.3 Other Late-Stage Pipeline Products 64
7.3.1 Cx601 64
7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 67
8 Market Outlook 71
8.1 Global Markets 71
8.1.1 Drivers and Barriers - Global Issues 71
9 China 76
9.1 Forecast 76
9.1.1 Key Events 78
9.2 Drivers and Barriers 79
9.2.1 Driver: Continued government-led schemes to increase patient access to healthcare facilities nationwide 79
9.2.2 Driver: The reliance of public hospitals on branded prescription drug sales boosts the use of these therapies 79
9.2.3 Barrier: Small CD patient population pool 80
9.2.4 Barrier: Widespread use and reliance on TCM 80
9.2.5 Barrier: The lack of appropriate patient cohorts hinders anti-TNF uptake 80
10 Appendix 81
10.1 Bibliography 81
10.2 Abbreviations 87
10.3 Methodology 90
10.4 Forecasting Methodology 90
10.4.1 Diagnosed CD Patients 90
10.4.2 Percent Drug-Treated Patients 91
10.4.3 Drugs Included in Each Therapeutic Class 91
10.4.4 General Pricing Assumptions 91
10.4.5 Individual Drug Assumptions 93
10.4.6 Generic Erosion 94
10.5 Physicians and Specialists Included in This Study 95
10.6 Primary Research - Prescriber Survey 96
10.7 About the Authors 97
10.7.1 Author/Reviewer 97
10.7.2 Global Head of Healthcare 97
10.8 About GlobalData 98
10.9 Disclaimer 98

1.1 List of Tables

Table 1: Symptoms of CD 18
Table 2: Treatment Guidelines for CD 22
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 24
Table 4: Leading Branded Drugs Used to Treat CD 30
Table 5: Product Profile - Remicade 32
Table 6: Remicade SWOT Analysis, 2013 35
Table 7: Product Profile - Humira 37
Table 8: Humira SWOT Analysis, 2013 40
Table 9: Product Profile - Cimzia 42
Table 10: Cimzia SWOT Analysis, 2013 44
Table 11: Product Profile - Tysabri 45
Table 12: Tysabri SWOT Analysis, 2013 49
Table 13: Summary of the Minor Therapeutic Classes in CD, 2013 50
Table 14: Biosimilars Pipeline, 2013 53
Table 15: Overall Unmet Needs in CD - Current Level of Attainment 57
Table 16: Clinical Unmet Needs in CD - Gap Analysis, 2013 60
Table 17: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 63
Table 18: Comparison of Therapeutic Classes in Development for CD, 2013 64
Table 19: Product Profile - Cx601 65
Table 20: Cx601 SWOT Analysis, 2013 66
Table 21: Product Profile - RHB-104 68
Table 22: RHB-104 SWOT Analysis, 2013 70
Table 23: Global CD Market - Drivers and Barriers, 2012-2022 71
Table 24: Sales Forecasts ($) for CD in China, 2012-2022 77
Table 25: Key Events Impacting Sales for CD in China, 2012-2022 78
Table 26: CD Market in China - Drivers and Barriers, 2012-2022 79
Table 27: Physicians Surveyed, By Country 96

1.2 List of Figures

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 14
Figure 2: Potential Biologic Drug Targets for CD 17
Figure 3: Patient Care Path for CD 23
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 63
Figure 5: Sales for CD in China by Drug Class, 2012-2022 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
R&D Drug Pipeline Database: 1-Year Subscription

R&D Drug Pipeline Database: 1-Year Subscription

  • $ 6600
  • Industry report
  • November 2016
  • by La Merie Publishing

R&D Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Single-use Bioprocessing Market by Product, Application, End User - Global Forecast to 2021

Single-use Bioprocessing Market by Product, Application, End User - Global Forecast to 2021

  • $ 6328
  • Industry report
  • October 2016
  • by MarketsandMarkets

Rising Biopharmaceutical Demand and Increasing Investments in R&D Activities Drive Growth of the Single-use Bioprocessing Market The global single-use bioprocessing market is projected to reach USD 5.44 ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.